Literature DB >> 16269599

Reproducibility of 3'-deoxy-3'-(18)F-fluorothymidine microPET studies in tumor xenografts in mice.

Jeffrey R Tseng1, Mangal Dandekar, Murugesan Subbarayan, Zhen Cheng, Jinha M Park, Stan Louie, Sanjiv S Gambhir.   

Abstract

UNLABELLED: 3'-Deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) has been used to image tumor proliferation in preclinical and clinical studies. Serial microPET studies may be useful for monitoring therapy response or for drug screening; however, the reproducibility of serial scans has not been determined. The purpose of this study was to determine the reproducibility of (18)F-FLT microPET studies.
METHODS: C6 rat glioma xenografts were implanted into nude mice (n = 9) and grown to mean diameters of 5-17 mm for approximately 2 wk. A 10-min acquisition was performed on a microPET scanner approximately 1 h after (18)F-FLT (1.9-7.4 MBq [50-200 muCi]) was injected via the tail vein. A second microPET scan was performed approximately 6 h later on the same day after reinjection of (18)F-FLT to assess for reproducibility. Most of the mice were studied twice within the same week (for a total of 17 studies). Images were analyzed by drawing an ellipsoidal region of interest (ROI) around the tumor xenograft activity. Percentage injected dose per gram (%ID/g) values were calculated from the mean activity in the ROIs. Coefficients of variation and differences in %ID/g values between studies from the same day were calculated to determine the reproducibility after subtraction of the estimated residual tumor activity from the first (18)F-FLT injection.
RESULTS: The coefficient of variation (mean +/- SD) for %ID/g values between (18)F-FLT microPET scans performed 6 h apart on the same day was 14% +/- 10%. The difference in %ID/g values between scans was -0.06% +/- 1.3%. Serum thymidine levels were mildly correlated with %ID/g values (R(2) = 0.40). Tumor size, mouse body weight, injected dose, and fasting state did not contribute to the variability of the scans; however, consistent scanning parameters were necessary to ensure accurate studies, in particular, controlling body temperature, the time of imaging after injection, and the ROI size.
CONCLUSION: (18)F-FLT microPET mouse tumor xenograft studies are reproducible with moderately low variability. Serial studies may be performed to assess for significant changes in therapy response or for preclinical drug development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16269599      PMCID: PMC4154806     

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  36 in total

1.  3'-18F-fluoro-3'-deoxy-L-thymidine: a new tracer for staging metastatic melanoma?

Authors:  David C P Cobben; Piet L Jager; Philip H Elsinga; Bram Maas; Albert J H Suurmeijer; Harald J Hoekstra
Journal:  J Nucl Med       Date:  2003-12       Impact factor: 10.057

2.  Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs.

Authors:  Jeffrey L Schwartz; Yasuko Tamura; Robert Jordan; John R Grierson; Kenneth A Krohn
Journal:  J Nucl Med       Date:  2003-12       Impact factor: 10.057

3.  Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging.

Authors:  Yuan-Chuan Tai; Ananya Ruangma; Douglas Rowland; Stefan Siegel; Danny F Newport; Patrick L Chow; Richard Laforest
Journal:  J Nucl Med       Date:  2005-03       Impact factor: 10.057

Review 4.  Statistical methods for assessing measurement error (reliability) in variables relevant to sports medicine.

Authors:  G Atkinson; A M Nevill
Journal:  Sports Med       Date:  1998-10       Impact factor: 11.136

5.  Thymidine concentrations in serum and urine of different animal species and man.

Authors:  H Nottebrock; R Then
Journal:  Biochem Pharmacol       Date:  1977-11-15       Impact factor: 5.858

6.  Reproducibility of metabolic measurements in malignant tumors using FDG PET.

Authors:  W A Weber; S I Ziegler; R Thödtmann; A R Hanauske; M Schwaiger
Journal:  J Nucl Med       Date:  1999-11       Impact factor: 10.057

7.  Basis of FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines.

Authors:  Jun Toyohara; Atsuo Waki; Shinji Takamatsu; Yoshiharu Yonekura; Yasuhiro Magata; Yasuhisa Fujibayashi
Journal:  Nucl Med Biol       Date:  2002-04       Impact factor: 2.408

8.  Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model.

Authors:  Aren van Waarde; David C P Cobben; Albert J H Suurmeijer; Bram Maas; Willem Vaalburg; Erik F J de Vries; Pieter L Jager; Harald J Hoekstra; Philip H Elsinga
Journal:  J Nucl Med       Date:  2004-04       Impact factor: 10.057

9.  Detection and grading of soft tissue sarcomas of the extremities with (18)F-3'-fluoro-3'-deoxy-L-thymidine.

Authors:  David C P Cobben; Philip H Elsinga; Albert J H Suurmeijer; Wim Vaalburg; Bram Maas; Piet L Jager; Harald J Hoekstra
Journal:  Clin Cancer Res       Date:  2004-03-01       Impact factor: 12.531

10.  Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3'-[(18)F]fluoro-3'-deoxythymidine ([(18)F]FLT) in pancreatic cancer cell lines.

Authors:  Ulrike Seitz; Martin Wagner; Bernd Neumaier; Edgar Wawra; Gerhard Glatting; Gerhard Leder; Roland M Schmid; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-06-04       Impact factor: 9.236

View more
  20 in total

1.  Reproducibility of static and dynamic (18)F-FDG, (18)F-FLT, and (18)F-FMISO MicroPET studies in a murine model of HER2+ breast cancer.

Authors:  Jennifer G Whisenant; Todd E Peterson; Jacob U Fluckiger; Mohammed Noor Tantawy; Gregory D Ayers; Thomas E Yankeelov
Journal:  Mol Imaging Biol       Date:  2013-02       Impact factor: 3.488

2.  Comparative Analysis of Human Nucleoside Kinase-Based Reporter Systems for PET Imaging.

Authors:  Jason T Lee; Hanwen Zhang; Maxim A Moroz; Yury Likar; Larissa Shenker; Nikita Sumzin; Jose Lobo; Juan Zurita; Jeffrey Collins; R Michael van Dam; Vladimir Ponomarev
Journal:  Mol Imaging Biol       Date:  2017-02       Impact factor: 3.488

3.  Integrin-targeted molecular imaging of experimental abdominal aortic aneurysms by (18)F-labeled Arg-Gly-Asp positron-emission tomography.

Authors:  Toshiro Kitagawa; Hisanori Kosuge; Edwin Chang; Michelle L James; Tomoaki Yamamoto; Bin Shen; Frederick T Chin; Sanjiv S Gambhir; Ronald L Dalman; Michael V McConnell
Journal:  Circ Cardiovasc Imaging       Date:  2013-08-30       Impact factor: 7.792

4.  Reproducibility study of [(18)F]FPP(RGD)2 uptake in murine models of human tumor xenografts.

Authors:  Edwin Chang; Shuangdong Liu; Gayatri Gowrishankar; Shahriar Yaghoubi; James Patrick Wedgeworth; Frederick Chin; Dietmar Berndorff; Volker Gekeler; Sanjiv S Gambhir; Zhen Cheng
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12-02       Impact factor: 9.236

5.  Reproducibility of 18F-FDG microPET studies in mouse tumor xenografts.

Authors:  Mangal Dandekar; Jeffrey R Tseng; Sanjiv S Gambhir
Journal:  J Nucl Med       Date:  2007-04       Impact factor: 10.057

Review 6.  Methods and challenges in quantitative imaging biomarker development.

Authors:  Richard G Abramson; Kirsteen R Burton; John-Paul J Yu; Ernest M Scalzetti; Thomas E Yankeelov; Andrew B Rosenkrantz; Mishal Mendiratta-Lala; Brian J Bartholmai; Dhakshinamoorthy Ganeshan; Leon Lenchik; Rathan M Subramaniam
Journal:  Acad Radiol       Date:  2015-01       Impact factor: 3.173

7.  Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas.

Authors:  Michelle S Bradbury; Dolores Hambardzumyan; Pat B Zanzonico; Jazmin Schwartz; Shangde Cai; Eva M Burnazi; Valerie Longo; Steven M Larson; Eric C Holland
Journal:  J Nucl Med       Date:  2008-02-20       Impact factor: 10.057

8.  PET hypoxia imaging with FAZA: reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice.

Authors:  M Busk; L S Mortensen; M Nordsmark; J Overgaard; S Jakobsen; K V Hansen; J Theil; J F Kallehauge; F P D'Andrea; T Steiniche; M R Horsman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10-18       Impact factor: 9.236

9.  Analysis and reproducibility of 3'-Deoxy-3'-[18F]fluorothymidine positron emission tomography imaging in patients with non-small cell lung cancer.

Authors:  Anthony F Shields; Jawana M Lawhorn-Crews; David A Briston; Sajad Zalzala; Shirish Gadgeel; Kirk A Douglas; Thomas J Mangner; Lance K Heilbrun; Otto Muzik
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

10.  Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET.

Authors:  Jeffrey R Tseng; Keon Wook Kang; Mangal Dandekar; Shahriar Yaghoubi; Joseph H Lee; James G Christensen; Stephen Muir; Patrick W Vincent; Neil R Michaud; Sanjiv S Gambhir
Journal:  J Nucl Med       Date:  2007-12-12       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.